{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"39.660","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"4,086,953,756","primaryexch":"香港交易所","ric":"2269.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"B","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.8221,"inline_upper_strike_price":"","sedol":"BL6B9P1","am":"1.78","iv":"","ew_strike":"","as":"39.060","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"39.040","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"500","update_time":"2025-09-28 00:06:03.0","lo52":"12.460","shares_issued_date":"2025年9月8日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"李革","underlying_ric":"2269.HK","hi52":"40.600","issuer_name":"藥明生物技術有限公司","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"38.060","mkt_cap":"159.63","f_aum_hkd":null,"ew_sub_per_to":"","ls":"39.060","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"-0.940","aum":"","issued_shares_class_B":null,"vo":"45.88","secondary_listing_flag":false,"listing_date":"2017年6月13日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"藥明生物技術有限公司","nm_s":"藥明生物","sym":"2269","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"葯明生物技術有限公司是一家主要從事向生物製劑行業的客戶提供就生物發現、開發及生產的端到端解決方案及服務的投資控股公司。該公司主要通過兩個分部運營其業務。生物葯分部主要從事提供生物葯的發現、開發和生產。葯明合聯（XDC）分部主要從事為抗體偶聯藥物（ADCs）及各種生物偶聯藥物提供合同研究、開發及生產組織（CRDMO）服務。該公司主要在國內和國外市場開展其業務。","op":"38.820","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港<br/>夏慤道16號<br/>遠東金融中心<br/>17樓","pc":"-2.35","days_to_expiry":null,"underlying_code":null,"pe":"44.87","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"40.000","isin":"KYG970081173","moneyness":""}},"qid":"1759073978992"}
